Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Enterprise Value (2016 - 2026)

Ultragenyx Pharmaceutical has reported Enterprise Value over the past 11 years, most recently at -$673.0 million for Q4 2025.

  • Quarterly Enterprise Value fell 11.61% to -$673.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$673.0 million through Dec 2025, down 11.61% year-over-year, with the annual reading at -$673.0 million for FY2025, 11.61% down from the prior year.
  • Enterprise Value was -$673.0 million for Q4 2025 at Ultragenyx Pharmaceutical, down from -$418.2 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$412.1 million in Q1 2024 and troughed at -$965.4 million in Q1 2021.
  • The 5-year median for Enterprise Value is -$608.8 million (2024), against an average of -$636.0 million.
  • Year-over-year, Enterprise Value crashed 151.98% in 2021 and then surged 50.25% in 2023.
  • A 5-year view of Enterprise Value shows it stood at -$740.2 million in 2021, then dropped by 1.02% to -$747.8 million in 2022, then increased by 22.75% to -$577.6 million in 2023, then fell by 4.39% to -$603.0 million in 2024, then dropped by 11.61% to -$673.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Enterprise Value are -$673.0 million (Q4 2025), -$418.2 million (Q3 2025), and -$480.6 million (Q2 2025).